Clinical trials: Digestive System Cancer
Rectal Cancer
Preoperative IMRT With Concurrent High-dose Vitamin C and mFOLFOX6 in Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the safety and efficacy of preoperative chemoradiotherapy (IMRT) with concurrent high-dose intravenous vitamin C and mFOLFOX6 in locally advanced rectal cancer patients.
- Trial name
- CORT (NCT04801511)
- Testing
- Vitamin C
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhou Fuxiang
Hepatocellular Carcinoma
Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma
The aim of this study is to observe the efficacy and safety of lenvatinib in preventing high-risk recurrence of hepatocellular carcinoma patients after liver transplantation.The cases are from patients with hepatocellular…
- Trial name
- NCT04168944
- Testing
- Lenvatinib, Immunosuppressive regimen
- Volunteers
- 108 people
- Sponsor
- RenJi Hospital
Colorectal Cancer
Computerized Tomographic Colonography Compared With Standard Diagnostic Procedures in Detecting Colorectal Neoplasia
RATIONALE: New diagnostic procedures such as computed tomographic colonography may provide a less invasive method of identifying patients who have colorectal neoplasia.
- Trial name
- ACRIN 6656 (NCT00005809)
- Testing
- computed tomography, diagnostic colonoscopy
- Where
- 11 sites in United States
- Sponsor
- American College of Radiology Imaging Network
Carcinoma, Hepatocellular, Hepatoma
Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma
Regorafenib and nivolumab are proven effective agents for the management of unresectable hepatocellular carcinoma patients. As preclinical studies have suggested potential synergism between antiangiogenic agents and immune…
- Trial name
- RENOBATE (NCT04310709)
- Testing
- Regorafenib/Nivolumab
- Where
- 3 sites in South Korea
- Volunteers
- 42 people
- Sponsor
- Asan Medical Center
Esophageal Neoplasms, Head and Neck Neoplasms
Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.
The purpose of this study is to observe the safety and effectiveness of the add-on of intraluminal brachytherapy with BRAXX esophageal brachytherapy applicator after definitive CCRT in patients with thoracic esophageal cancer.
- Conditions
- Esophageal Neoplasms, Head and Neck Neoplasms, Gastrointestinal Neoplasms, Digestive System Diseases
- Trial name
- NCT06365866
- Testing
- "BRAXX" Esophageal Brachytherapy Applicator., Add-on of intraluminal brachytherapy
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Colon Cancer
Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX
Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX
- Trial name
- NCT01310972
- Testing
- Registry
- Where
- Saudi Arabia
- Volunteers
- 6 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Oropharynx Cancer, Oral Cavity
Oncology, Undernutrition and Sensoriality: Links, Mechanisms and Levers for Action
Cancers of the upper aerodigestive tract account for around 4% of all malignant tumours worldwide. Colon and liver cancer are the most common digestive cancers.
- Conditions
- Oropharynx Cancer, Oral Cavity, Colon Cancer, Liver Cancer
- Trial name
- ONDES (NCT06600295)
- Testing
- tests/questionnaires, biological samples, evaluation
- Where
- France
- Volunteers
- 306 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Colorectal Cancer Stage IV
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective as the same regimen given continuously, in unresectable metastatic RAS and BRAF wild type colorectal cancer patients.
- Trial name
- IMPROVE (NCT04425239)
- Testing
- Panitumumab
- Where
- Italy
- Volunteers
- 151 people
- Sponsor
- National Cancer Institute, Naples
Colorectal Neoplasms, Microsatellite Instability
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
In this study, MMRd metastatic colorectal cancer (mCRC) patients who failed standard therapies will undergo treatment with pembrolizumab, while RAS-extended mutated MMR-proficient mCRC patients will be tested for…
- Trial name
- ARETHUSA (NCT03519412)
- Testing
- temozolomide (induction),, pembrolizumab (treatment)
- Where
- 4 sites in Italy
- Volunteers
- 107 people
- Sponsor
- IFOM ETS - The AIRC Institute of Molecular Oncology
Hepatocellular Carcinoma, Hepatocellular Cancer
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for curative surgery (with/without local ablation).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer, Colorectal Carcinoma
- Trial name
- NCT04912765
- Testing
- Neoantigen Dendritic Cell Vaccine, Nivolumab
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- National Cancer Centre, Singapore
Pancreatic Cancer, Pancreas Disease
Artificial Intelligence in Endoscopic Ultrasound
The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures.
- Conditions
- Pancreatic Cancer, Pancreas Disease, Pancreatic Cyst
- Trial name
- NCT06564571
- Testing
- Patients undergoing endoscopic ultrasound procedures
- Where
- United States
- Volunteers
- 310 people
- Sponsor
- Orlando Health, Inc.
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined…
- Trial name
- KontRASt-R (NCT07468071)
- Testing
- Opnurasib, TNO155, trametinib
- Where
- 21 sites in Belgium, Canada and 8 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Cholangiocarcinoma
Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
Previous reports suggest benefit of neoadjuvant chemotherapy/chemoradiation treatment for borderline resectable cholangiocarcinoma.
- Trial name
- NCT03603834
- Testing
- mFOLFOXIRI
- Where
- Thailand
- Volunteers
- 25 people
- Sponsor
- Khon Kaen University
Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations.
- Conditions
- Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
- Trial name
- NCT04042831
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Academic and Community Cancer Research United
Ileostomy - Stoma, Rectal Cancer
Early Ileostomy Closure for Rectal Cancer Patients in North America
Our preliminary work demonstrates that there is buy-in from both patients and surgeons with regards to early ileostomy closure (EIC) for select rectal cancer patients undergoing restorative proctectomy (RP) and diverting loop…
- Trial name
- NCT05027737
- Testing
- Early Ileostomy Closure
- Where
- 4 sites in Canada
- Volunteers
- 118 people
- Sponsor
- Jewish General Hospital
Carcinoma, Hepatocellular
A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinoma and Its Correlates in Pakistan
This study aims to explore the levels of alpha-fetoprotein (AFP), a protein often elevated in liver cancer, in patients with hepatocellular carcinoma (HCC).
- Trial name
- NCT06629857
- Where
- Pakistan
- Volunteers
- 94 people
- Sponsor
- Darul Sehat Hospital
Primary Hepatocellular Carcinoma
Clinical Study of MAK Immune Cells in the Treatment of PHC
The investigators will plan to recruit 20 patients with liver cancer CNLC stage Ⅲa and Ⅲb who are older than 18 years old. Peripheral blood mononuclear cells were obtained and then the MAK(Mixed-activated Killer) cells were…
- Trial name
- NCT05242757
- Testing
- Mixed-activated Killer Immune Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Zhongnan Hospital
Colorectal Cancer
Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC
This study select the diagnosis of postoperative colorectal cancer patients with stage II/III to adjuvant chemotherapy, and received 2 weeks and 3 weeks xelox adjuvant treatment process until disease progression or patients died…
- Trial name
- NCT03564912
- Testing
- Capecitabine Oral Tablet [Xeloda]
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Zhejiang University
Pancreatic Cancer
Diet and Exercise After Pancreatic Cancer
Determine feasibility of a randomized controlled trial (RCT) in pancreatic (\& other foregut) cancer patients comparing the effects of diet alone vs. diet+exercise on functional and clinical outcomes.
- Trial name
- PACE (NCT03187028)
- Testing
- Diet Only, Diet + Exercise
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Alabama at Birmingham
Gastrointestinal Tumors, Pancreatic Tumors
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
The purpose of this study is to explore the efficacy and safety of everolimus administered as a first-line treatment in newly-diagnosed patients with advanced or inoperable Gastrointestinal (GI) or pancreatic neuroendocrine…
- Conditions
- Gastrointestinal Tumors, Pancreatic Tumors, Gastrointestinal Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors
- Trial name
- NCT01648465
- Testing
- Everolimus
- Where
- 12 sites in Greece
- Volunteers
- 25 people
- Sponsor
- Hellenic Cooperative Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.